$4396 | SAVE $599 | Single User
$8791 | SAVE $1,199 | Site License
$13187 | SAVE $1,798 | Enterprise License

Seasonal Influenza Vaccines - Japan Drug Forecast and Market Analysis to 2025
[Report Updated: 01-11-2016]

Published by Global Data: 01 Nov 2016 | 43277 | In Stock
Related Topics: Vaccine

Introduction

Seasonal Influenza Vaccines - Japan Drug Forecast and Market Analysis to 2025

Summary

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.

The projected drivers for growth of the Japanese influenza vaccine market include the entrance of large multinational firms into the marketplace, a government commitment to educating the populace about the importance of preventative medicine (including vaccination), and growth of the elderly population.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Overview of Seasonal Influenza Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in Japan from 2015-2025.

- Analysis of the impact of key events as well the drivers and restraints affecting Japan Seasonal Influenza Vaccines market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for Seasonal Influenza Vaccines.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of drug performance

- Obtain sales forecast for drugs from 2015-2025 in Japan.

Table of Contents
for Seasonal Influenza Vaccines - Japan Drug Forecast and Market Analysis to 2025 [Report Updated: 01-11-2016]

  • 1 Table of Contents

    1 Table of Contents 2

    1.1 List of Tables 6

    1.2 List of Figures 10

    2 Introduction 11

    2.1 Catalyst 11

    2.2 Related Reports 12

    2.3 Upcoming Related Reports 12

    3 Disease Overview 13

    3.1 Etiology and Pathophysiology 13

    3.1.1 Etiology 13

    3.1.2 Pathophysiology 18

    3.1.3 Symptoms and Prognosis 19

    4 Disease Management 21

    4.1 Seasonal Influenza Immunization Policy 21

    4.1.1 Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines 22

    4.2 Japan 24

    4.2.1 Influenza Immunization Recommendations and Policies 25

    4.2.2 Clinical Practice 27

    5 Competitive Assessment 30

    5.1 Overview 30

    5.2 Product Profiles - Major Brands, Inactivated Vaccines 32

    5.2.1 Fluzone Quadrivalent 32

    5.2.2 Fluzone High-Dose 38

    5.2.3 Fluzone Intradermal 45

    5.2.4 Vaxigrip 53

    5.2.5 Fluarix Tetra 59

    5.2.6 Fluvirin 66

    5.2.7 Afluria 71

    5.2.8 Agrippal 77

    5.3 Product Profiles - Major Brands, Inactivated Vaccines (Adjuvanted) 81

    5.3.1 Fluad 81

    5.4 Product Profiles - Major Brands, Live-Attenuated Vaccines 88

    5.4.1 FluMist Quadrivalent 88

    5.5 Product Profiles - Major Brands, Cell Cultured Vaccines 96

    5.5.1 Flublok 96

    5.5.2 Flucelvax 103

    5.6 Other Seasonal Influenza Vaccines 110

    5.6.1 Influvac 110

    5.6.2 Minor Brands 112

    6 Unmet Needs and Opportunity Analysis 113

    6.1 Overview 113

    6.2 Higher Level of Public Awareness and Positive Perception of Influenza Vaccines 117

    6.2.1 Unmet Need 117

    6.2.2 Gap Analysis 118

    6.2.3 Opportunity 121

    6.3 Immunization Policies Targeting Children and Adolescents 122

    6.3.1 Unmet Need 122

    6.3.2 Gap Analysis 123

    6.3.3 Opportunity 123

    6.4 Enhanced Vaccine Efficacy in High-Risk Groups 125

    6.4.1 Unmet Need 125

    6.4.2 Gap Analysis 126

    6.4.3 Opportunity 128

    6.5 Vaccines Leveraging Innovative and Efficient Manufacturing Technologies 129

    6.5.1 Unmet Need 129

    6.5.2 Gap Analysis 130

    6.5.3 Opportunity 131

    6.6 Improving the Cost-Effectiveness of Influenza Vaccines 132

    6.6.1 Unmet Need 132

    6.6.2 Gap Analysis 133

    6.6.3 Opportunity 134

    6.7 Vaccines with Broader Influenza Strain Coverage 135

    6.7.1 Unmet Need 135

    6.7.2 Gap Analysis 136

    6.7.3 Opportunity 137

    6.8 Improved Vaccine Safety Profile 138

    6.8.1 Unmet Need 138

    6.8.2 Gap Analysis 139

    6.8.3 Opportunity 140

    7 Pipeline Assessment 141

    7.1 Overview 141

    7.2 Promising Vaccines in Clinical Development 142

    7.2.1 Seasonal Influenza VLP Vaccine 147

    7.2.2 VN-100 156

    7.2.3 Quadrivalent Seasonal Influenza VLP Vaccine 164

    7.3 Promising Vaccines in Early-Stage Development 172

    7.3.1 FLU-v 173

    7.3.2 M-001 174

    7.3.3 TAK-850 175

    7.3.4 VAX-2012Q 175

    7.4 Other Vaccines in Development Outside the 7MM 176

    8 Market Outlook 177

    8.1 Japan 177

    8.1.1 Forecast 177

    8.1.2 Key Events 181

    8.1.3 Drivers and Barriers 182

    9 Appendix 183

    9.1 Bibliography 183

    9.2 Abbreviations 221

    9.3 Methodology 225

    9.4 Forecasting Methodology 225

    9.4.1 Vaccine Coverage 225

    9.4.2 Vaccines Included 226

    9.4.3 Key Launch Dates 226

    9.4.4 Influenza Vaccine Tender System Assumptions 227

    9.4.5 General Pricing Assumptions 228

    9.4.6 Individual Vaccine Assumptions 229

    9.4.7 Pricing of Pipeline Agents 237

    9.5 Primary Research - KOLs Interviewed for this Report 238

    9.6 Primary Research - Prescriber Survey 241

    9.7 About the Authors 242

    9.7.1 Analyst 242

    9.7.2 Therapy Area Director 242

    9.7.3 Epidemiologists 243

    9.7.4 Director of Epidemiology 244

    9.7.5 Global Director of Therapy Analysis and Epidemiology 244

    9.8 About GlobalData 245

    9.9 Disclaimer 245

List Of Tables
in Seasonal Influenza Vaccines - Japan Drug Forecast and Market Analysis to 2025 [Report Updated: 01-11-2016]

1.1 List of Tables

Table 1: Notable Influenza Pandemics 18

Table 2: Influenza Symptoms 20

Table 3: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016 22

Table 4: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016 24

Table 5: Country Profile -Japan 25

Table 6: Leading Seasonal Influenza Vaccines, 2016 31

Table 7: Product Profile - Fluzone Quadrivalent 33

Table 8: Immunogenicity Profile of Fluzone Quadrivalent 34

Table 9: Local and Systemic AEs of Fluzone Quadrivalent 35

Table 10: Fluzone Quadrivalent SWOT Analysis, 2016 36

Table 11: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015-2025 38

Table 12: Product Profile - Fluzone High-Dose 39

Table 13: Immunogenicity of Fluzone High-Dose Compared with Fluzone 41

Table 14: Local and Systemic AEs of Fluzone High-Dose 42

Table 15: Fluzone High-Dose SWOT Analysis, 2016 43

Table 16: Global Sales Forecast ($m) for Fluzone High-Dose, 2015-2025 45

Table 17: Product Profile - Fluzone Intradermal 47

Table 18: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent 49

Table 19: Local andsystemic AEs of Fluzone Intradermal Quadrivalent 50

Table 20: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016 51

Table 21: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015-2025 53

Table 22: Product Profile - Vaxigrip 55

Table 23: Cumulative Incidence of Influenza Infection in Children 56

Table 24: Local and Systemic AEs of Vaxigrip 57

Table 25: Vaxigrip SWOT Analysis, 2016 57

Table 26: Global Sales Forecast ($m) for Vaxigrip, 2015-2025 59

Table 27: Product Profile - Fluarix Tetra 61

Table 28: Immunogenicity Profile of Fluarix Tetra 62

Table 29: Local and Systemic AEs of Fluarix Tetra 63

Table 30: Fluarix Tetra SWOT Analysis, 2016 64

Table 31: Global Sales Forecast ($m) for Fluarix Tetra, 2015-2025 66

Table 32: Product Profile - Fluvirin 67

Table 33: Immunogenicity of Fluvirin in Adults 68

Table 34: Local and Systemic AEs of Fluvirin 69

Table 35: Fluvirin SWOT Analysis, 2016 70

Table 36: Global Sales Forecast ($m) for Fluvirin, 2015-2025 71

Table 37: Product Profile - Afluria 72

Table 38: Immunogenicity of Afluria in Adults 73

Table 39: Local and Systemic AEs of Afluria 74

Table 40: Afluria SWOT Analysis, 2016 75

Table 41: Global Sales Forecast ($m) for Afluria, 2015-2025 76

Table 42: Product Profile - Agrippal 78

Table 43: Immunogenicity of Agrippal 79

Table 44: Local and Systemic AEs of Agrippal 79

Table 45: Agrippal SWOT Analysis, 2016 80

Table 46: Global Sales Forecast ($m) for Agrippal, 2015-2025 81

Table 47: Product Profile - Fluad 83

Table 48: Immunogenicity Comparison of Fluad Versus Agriflu 84

Table 49: Local and Systemic AEs of Fluad 85

Table 50: Fluad SWOT Analysis, 2016 86

Table 51: Global Sales Forecast ($m) for Fluad, 2015-2025 88

Table 52: Product Profile - FluMist Quadrivalent 90

Table 53: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent 92

Table 54: AEs of FluMist Quadrivalent 93

Table 55: FluMist Quadrivalent SWOT Analysis, 2016 93

Table 56: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015-2025 95

Table 57: Product Profile - Flublok 97

Table 58: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose 99

Table 59: Local and Systemic AEs of Flublok 100

Table 60: Flublok SWOT Analysis, 2016 101

Table 61: Global Sales Forecast ($m) for Flublok, 2015-2025 103

Table 62: Product Profile - Flucelvax 105

Table 63: Immunogenicity of Flucelvax 106

Table 64: Local and Systemic AEs of Flucelvax 107

Table 65:Flucelvax SWOT Analysis, 2016 108

Table 66: Global Sales Forecast ($m) for Flucelvax, 2015-2025 110

Table 67: Summary of Other Marketed Seasonal Influenza Vaccines, 2016 112

Table 68: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016 116

Table 69: Seasonal Influenza Vaccines - Late-Stage Pipeline, 2016 143

Table 70: Quadrivalent Versions of Marketed Vaccines 146

Table 71: Product Profile - Seasonal Influenza VLP Vaccine 149

Table 72: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016 154

Table 73: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015-2025 156

Table 74: Product Profile - VN-100 158

Table 75: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine 159

Table 76: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine 160

Table 77: VN-100 SWOT Analysis, 2016 163

Table 78: Global Sales Forecast ($m) for VN-100, 2015-2025 164

Table 79: Product Profile - Quadrivalent Seasonal Influenza VLP Vaccine 166

Table 80: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016 170

Table 81: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015-2025 172

Table 82: Promising Vaccines in Early-Stage Development, 2016 173

Table 83: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016 176

Table 84: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Japan, 2015-2025 179

Table 85: Key Events Impacting Sales for Seasonal Influenza in Japan 2015‒2025 181

Table 86: Japan Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 182

Table 87: Key Launch Dates 227

Table 88: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 241

List Of Figures, Charts and Diagrams
in Seasonal Influenza Vaccines - Japan Drug Forecast and Market Analysis to 2025 [Report Updated: 01-11-2016]

1.2 List of Figures

Figure 1: Influenza Virus Structure 15

Figure 2: Seasonal Influenza Vaccines - Phase II/Phase III Pipeline, 2016 143

Figure 3: Competitive Assessment of the Late-Stage Pipeline Vaccines for Seasonal Influenza, 2015-2025 144

Figure 4: Sales of Seasonal Influenza Vaccines by Class in Japan, 2015 and 2025 180

Additional Details

Publisher

Global Data

Publisher Information

Reference

43277 | GDHC373CFR

Number of Pages

246

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! Seasonal Influenza: Competitive Landscape to 2026
Seasonal Influenza: Competitive Landscape to 2026SummaryInfluenza, often referred to as the flu, is ...
08 Nov 2018 by Global Data USD $3,076 (normally
USD $3,495)
More Info
SAVE 12% today! Seasonal Influenza Vaccine Market Size, Country Outlook, Vaccination Analysis, Pipeline Insights, Clinical Trials Statement, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast,2016 to 2022
Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven majo...
21 Nov 2016 by DPI Research USD $1,760 (normally
USD $2,000)
More Info
SAVE 12% today! EpiCast Report: Seasonal Influenza - Epidemiology Forecast to 2025
EpiCast Report: Seasonal Influenza - Epidemiology Forecast to 2025SummaryInfluenza, commonly known a...
01 Nov 2016 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Seasonal Influenza - Epidemiology Forecast to 2025
EpiCast Report: Seasonal Influenza - Epidemiology Forecast to 2025SummaryInfluenza, commonly known a...
01 Nov 2016 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025
PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025SummaryIn...
01 Nov 2016 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! Seasonal Influenza Vaccines - US Drug Forecast and Market Analysis to 2025
Seasonal Influenza Vaccines - US Drug Forecast and Market Analysis to 2025SummaryInfluenza, often re...
01 Nov 2016 by Global Data USD $4,396 (normally
USD $4,995)
More Info
SAVE 12% today! Seasonal Allergic Rhinitis Global Clinical Trials Review, H2, 2016
Seasonal Allergic Rhinitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
30 Sep 2016 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Seasonal Affective Disorder (SAD) Global Clinical Trials Review, H2, 2016
Seasonal Affective Disorder (SAD) Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinica...
27 Jul 2016 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Seasonal Affective Disorder (SAD) Global Clinical Trials Review, H2, 2016
Seasonal Affective Disorder (SAD) Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinica...
27 Jul 2016 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Seasonal Influenza Global Clinical Trials Review, H2, 2015
Seasonal Influenza Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report,...
30 Dec 2015 by Global Data USD $2,200 (normally
USD $2,500)
More Info

This report is published by Global Data

Download Free Report Summary PDF

Seasonal Influenza Vaccines - Japan Drug Forecast and Market Analysis to 2025 [Report Updated: 01-11-2016] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...